Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. Jan 2001; 84(2): 157–163.
PMCID: PMC2363714
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine
K A Jaeckle,1 S Phuphanich,1 M J van den Bent,1 R Aiken,1 T Batchelor,1 T Campbell,1 D Fulton,1 M Gilbert,1 D Heros,1 L Rogers,1 S J O'Day,1 W Akerley,1 J Allen,1 S Baidas,1 S Z Gertler,1 H S Greenberg,1 S LaFollette,1 G Lesser,1 W Mason,1 L Recht,1 E Wong,1 M C Chamberlain,1 A Cohn,1 M J Glantz,1 J C Gutheil,1 B Maria,1 P Moots,1 P New,1 C Russell,1 W Shapiro,1 L Swinnen,1 and S B Howell1
1From the M.D. Anderson Cancer Center; H. Lee Moffitt Cancer Center; Dr. Daniel den Hoed Cancer Clinic; Thomas Jefferson University Hospital; Massachusetts General Hospital; Sharp Healthcare; Cross Cancer Institute; the Emory Clinic; Mt. Sinaiomprehensive Cancer Center; Wayne State University Health Center; the John Wayne Cancer Institute; Memorial Hospital of Rhode Island; New York University Medical Center; Georgetown University Medical Center; Ottowa Regional Cancer Center; University ofichigan Hospitals; Rush Cancer Institute; Comprehensive Cancer Center of Wake Forrest University; Ontario Cancer Center; University of Massachusetts Medical School; Beth Israel Deaconess Medical Center; University of California San Diego; University of colorado; University of Florida; Vanderbilt University Medical Center; University of Texas, San Antonio; Norris Cancer Center; Barrow Neurological Institute; and Loyola University
*Author for correspondence:
Received May 3, 2000; Revised September 8, 2000; Accepted October 11, 2000.
DepoCyte is a slow-release formulation of cytarabine designed for intrathecal administration. The goal of this multi-centre cohort study was to determine the safety and efficacy of DepoCyte for the intrathecal treatment of neoplastic meningitis due to breast cancer. DepoCyte 50 mg was injected once every 2 weeks for one month of induction therapy; responding patients were treated with an additional 3 months of consolidation therapy. All patients had metastatic breast cancer and a positive CSF cytology or neurologic findings characteristic of neoplastic meningitis. The median number of DepoCyte doses was 3, and 85% of patients completed the planned 1 month induction. Median follow up is currently 19 months. The primary endpoint was response, defined as conversion of the CSF cytology from positive to negative at all sites known to be positive, and the absence of neurologic progression at the time the cytologic conversion was documented. The response rate among the 43 evaluable patients was 28% (CI 95%: 14–41%); the intent-to-treat response rate was 21% (CI 95%: 12–34%). Median time to neurologic progression was 49 days (range 1–515+); median survival was 88 days (range 1–515+), and 1 year survival is projected to be 19%. The major adverse events were headache and arachnoiditis. When drug-related, these were largely of low grade, transient and reversible. Headache occurred on 11% of cycles; 90% were grade 1 or 2. Arachnoiditis occurred on 19% of cycles; 88% were grade 1 or 2. DepoCyte demonstrated activity in neoplastic meningitis due to breast cancer that is comparable to results reported with conventional intrathecal agents. However, this activity was achieved with one fourth as many intrathecal injections as typically required in conventional therapy. The every 2 week dose schedule is a major advantage for both patients and physicians. © 2001 Cancer Research Campaign
Full Text
The Full Text of this article is available as a PDF (68K).
Articles from British Journal of Cancer are provided here courtesy of
Cancer Research UK